Trabecular meshwork: A pivotal target for evolving glaucoma treatments.
Wan Yue, Guo Xinzheng, Wang Ningli
AI Summary
The trabecular meshwork's dysfunction is central to glaucoma's elevated eye pressure. New therapies, from drugs to gene and cell-based approaches, are targeting the TM to restore function and improve glaucoma treatment.
Abstract
The trabecular meshwork (TM) is a key regulator of intraocular pressure (IOP) through its role in facilitating aqueous humor outflow. Pathological alterations in the TM-such as reduced cellularity, impaired extracellular matrix turnover, and increased biomechanical stiffness-raise outflow resistance, leading to elevated IOP and contributing to glaucoma pathogenesis. We summarize the TM's anatomical structure, cellular heterogeneity, and biomechanical properties, emphasizing its central role in maintaining IOP homeostasis. It also outlines TM alterations across different glaucoma subtypes and highlights key molecular mechanisms underlying TM dysfunction, including dysregulation of Rho GTPase signaling, nitric oxide (NO) pathways, TGF-β2-induced fibrosis, lipid signaling, and endoplasmic reticulum stress. Advancements in TM-targeted therapies include pharmacologic interventions (e.g., Rho kinase inhibitors, NO donors), non-invasive approaches (e.g., laser trabeculoplasty, ultrasound, sonic therapies), and minimally invasive glaucoma surgeries. Emerging gene therapies that target TM outflow pathway show promise for long-lasting IOP control. Additionally, cell-based therapies aiming to restore TM cellularity and function represent a novel regenerative strategy. Despite significant progress, challenges remain in optimizing delivery methods, sustaining therapeutic efficacy, and ensuring safety. We highlight the evolving landscape of TM-targeted interventions and underscore the importance of continued innovation in glaucoma management.
MeSH Terms
Shields Classification
Key Concepts6
Advancements in trabecular meshwork (TM)-targeted therapies include pharmacologic interventions (e.g., Rho kinase inhibitors, NO donors), non-invasive approaches (e.g., laser trabeculoplasty, ultrasound, sonic therapies), and minimally invasive glaucoma surgeries.
Emerging gene therapies that target the trabecular meshwork (TM) outflow pathway show promise for long-lasting intraocular pressure (IOP) control.
Cell-based therapies aiming to restore trabecular meshwork (TM) cellularity and function represent a novel regenerative strategy for glaucoma.
The trabecular meshwork (TM) is a key regulator of intraocular pressure (IOP) through its role in facilitating aqueous humor outflow.
Pathological alterations in the trabecular meshwork (TM), such as reduced cellularity, impaired extracellular matrix turnover, and increased biomechanical stiffness, raise outflow resistance, leading to elevated intraocular pressure (IOP) and contributing to glaucoma pathogenesis.
Key molecular mechanisms underlying trabecular meshwork (TM) dysfunction include dysregulation of Rho GTPase signaling, nitric oxide (NO) pathways, TGF-β2-induced fibrosis, lipid signaling, and endoplasmic reticulum stress.
Related Articles5
Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs.
Basic ScienceMorphologic proof of the toxicity of mitomycin C on the ciliary body in relation to different application methods.
Basic ScienceRegarding 'Management of Primary Angle-Closure Glaucoma'.
LetterRelationship Between Chemokine in Aqueous Humor and Primary Glaucoma: A Meta-Analysis.
Meta-AnalysisEffect of Anti-Inflammatory Regimen on Selective Laser Trabeculoplasty Outcomes: A Randomized Controlled Trial.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.